Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
Eur Biophys J ; 47(3): 271-290, 2018 Apr.
Article En | MEDLINE | ID: mdl-28975383

Membrane-associated carbonic anhydrase (CA) isoform IV participates in carbon metabolism and pH homeostasis and is implicated in the development of eye diseases such as retinitis pigmentosa and glaucoma. A series of substituted benzenesulfonamides were designed and their binding affinity to CA IV was determined by fluorescent thermal shift assay and isothermal titration calorimetry (ITC). Compound [(4-chloro-2-phenylsulfanyl-5-sulfamoyl-benzoyl)amino]propyl acetate (19) bound CA IV with the K d of 1.0 nM and exhibited significant selectivity over the remaining 11 human CA isoforms. The compound could be developed as a drug targeting CA IV. Various forms of recombinant CA IV were produced in Escherichia coli and mammalian cell cultures. Comparison of their temperature stability in various buffers and salt solutions demonstrated that CA IV is most stable at slightly alkaline conditions and at elevated sodium sulfate concentrations. High-resolution X-ray crystallographic structures of ortho-Cl and meta-thiazole-substituted benzene sulfonamide in complex with CA IV revealed the position of and interactions between the ligand and the protein. Sulfonamide inhibitor binding to CA IV is linked to several reactions-the deprotonation of the sulfonamide amino group, the protonation of CA-Zn(II)-bound hydroxide at the active site of CA IV, and the compensating reactions of the buffer. The dissection of binding-linked reactions yielded the intrinsic thermodynamic parameters, characterizing the interaction between CA IV and the sulfonamides in the binding-able protonation forms, including Gibbs energy, enthalpy, and entropy, that could be used for the characterization of binding to any CA in the process of drug design.


Carbonic Anhydrase IV/antagonists & inhibitors , Carbonic Anhydrase IV/metabolism , Carbonic Anhydrase Inhibitors/metabolism , Recombinant Proteins/metabolism , Carbonic Anhydrase IV/chemistry , Carbonic Anhydrase Inhibitors/pharmacology , Catalytic Domain , Humans , Ligands , Models, Molecular , Protein Binding , Recombinant Proteins/chemistry , Thermodynamics
2.
J Med Chem ; 57(22): 9435-46, 2014 Nov 26.
Article En | MEDLINE | ID: mdl-25358084

Human carbonic anhydrase IX (CA IX) is highly expressed in tumor tissues, and its selective inhibition provides a potential target for the treatment of numerous cancers. Development of potent, highly selective inhibitors against this target remains an unmet need in anticancer therapeutics. A series of fluorinated benzenesulfonamides with substituents on the benzene ring was designed and synthesized. Several of these exhibited a highly potent and selective inhibition profile against CA IX. Three fluorine atoms significantly increased the affinity by withdrawing electrons and lowering the pKa of the benzenesulfonamide group. The bulky ortho substituents, such as cyclooctyl or even cyclododecyl groups, fit into the hydrophobic pocket in the active site of CA IX but not CA II, as shown by the compound's co-crystal structure with chimeric CA IX. The strongest inhibitor of recombinant human CA IX's catalytic domain in human cells achieved an affinity of 50 pM. However, the high affinity diminished the selectivity. The most selective compound for CA IX exhibited 10 nM affinity. The compound that showed the best balance between affinity and selectivity bound with 1 nM affinity. The inhibitors described in this work provide the basis for novel anticancer therapeutics targeting CA IX.


Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrases/chemistry , Drug Design , Benzene/chemistry , Calorimetry , Carbon Dioxide/chemistry , Carbonic Anhydrase IV/chemistry , Catalysis , Catalytic Domain , Crystallization , Crystallography, X-Ray , Humans , Hydrogen-Ion Concentration , Kinetics , Neoplasms/drug therapy , Protein Binding , Protein Conformation , Recombinant Proteins/chemistry , Sulfonamides/chemistry , Thermodynamics
3.
PLoS One ; 7(5): e36899, 2012.
Article En | MEDLINE | ID: mdl-22655030

The design of specific inhibitors against the Hsp90 chaperone and other enzyme relies on the detailed and correct understanding of both the thermodynamics of inhibitor binding and the structural features of the protein-inhibitor complex. Here we present a detailed thermodynamic study of binding of aryl-dihydroxyphenyl-thiadiazole inhibitor series to recombinant human Hsp90 alpha isozyme. The inhibitors are highly potent, with the intrinsic K(d) approximately equal to 1 nM as determined by isothermal titration calorimetry (ITC) and thermal shift assay (TSA). Dissection of protonation contributions yielded the intrinsic thermodynamic parameters of binding, such as enthalpy, entropy, Gibbs free energy, and the heat capacity. The differences in binding thermodynamic parameters between the series of inhibitors revealed contributions of the functional groups, thus providing insight into molecular reasons for improved or diminished binding efficiency. The inhibitor binding to Hsp90 alpha primarily depended on a large favorable enthalpic contribution combined with the smaller favorable entropic contribution, thus suggesting that their binding was both enthalpically and entropically optimized. The enthalpy-entropy compensation phenomenon was highly evident when comparing the inhibitor binding enthalpies and entropies. This study illustrates how detailed thermodynamic analysis helps to understand energetic reasons for the binding efficiency and develop more potent inhibitors that could be applied for therapeutic use as Hsp90 inhibitors.


HSP90 Heat-Shock Proteins/metabolism , Thiadiazoles/chemistry , Thiadiazoles/pharmacology , Calorimetry , HSP90 Heat-Shock Proteins/antagonists & inhibitors , Humans , Protein Binding , Thermodynamics
...